Pacira BioSciences, Inc.

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 14/06/2024 BST			5-day change	1st Jan Change
28.13 ^USD	-0.85%		-1.54%	-16.63%

05-14	Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
05-10	Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	MT

Pacira Pharmaceuticals, Inc. Announces Termination of Taunia Markvicka as Senior Vice President, Commercial Strategy

January 08, 2016 at 09:53 pm

On January 7, 2016, Taunia Markvicka terminated her employment as Senior Vice President, Commercial Strategy of Pacira Pharmaceuticals, Inc.

Latest news about Pacira BioSciences, Inc.

Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM	05-14
Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	05-10	MT
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating	05-08	MT
Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M	05-07	MT
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares.	05-07	CI
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024	05-07	CI
Pacira BioSciences, Inc. authorizes a Buyback Plan.	05-06	CI
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	03-13
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	03-13	MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	03-13	DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	03-13	CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	03-08	MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	03-01	MT
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	02-29	MT
Transcript : Pacira BioSciences, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	02-29	CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	02-29	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	02-29	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	02-29	MT
North American Morning Briefing : Fed's Preferred -2-	02-29	DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	02-15	CI
Pacira BioSciences Awarded Group Purchasing Agreement with Premier	02-07	MT

Chart Pacira BioSciences, Inc.

Duration

Period

More charts

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pacira BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.13 USD

Average target price

44.9 USD

Spread / Average Target

+59.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PACIRA BIOSCIENCES, INC.	-16.63%	1.31B
NOVO NORDISK A/S	+41.83%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+17.96%	246B
ROCHE HOLDING AG	+0.49%	225B
NOVARTIS AG	+10.60%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals

Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Pacira Pharmaceuticals, Inc. Announces Termination of Taunia Markvicka as Senior Vice President, Commercial Strategy

Latest news about Pacira BioSciences, Inc.

Chart Pacira BioSciences, Inc.

Company Profile

Income Statement Evolution

Ratings for Pacira BioSciences, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals